共 50 条
- [21] A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple MyelomaBLOOD, 2014, 124 (21)Bensinger, William I.Vescio, RobertGasparetto, CristinaCamacho, Elber S.Nath, RajneeshGomes, Christina L.Smith, David D.Shah, Jatin J.Durie, Brian G. M.
- [22] A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple MyelomaBLOOD, 2015, 126 (23)Silvennoinen, RaijaAnttila, PekkaSaily, MarjaanaLundan, TuijaHeiskanen, JouniSiitonen, TimoKakko, SakariPutkonen, MerviOllikainen, HannaTerava, VenlaPartanen, AnuLaunonen, KirsiRasanen, AnuSiklo, AnuSuominen, MerjaBazia, PiotrKananen, KristiinaSelander, TuomasKuittinen, TaruPorkka, KimmoRemes, KariJantunen, Esa
- [23] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in ChinaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S104 - S104Zhuang, ZheTian, YingYu, HongShi, LeiTian, Wei-weiLiu, QinhuaZou, DongmeiDong, FeiFeng, RuMa, YanpingLiu, ShuangjiaoLiu, HuiJing, HongmeiSun, WanlingMa, Liang-MingBao, LiFu, RongWu, YinChen, WenmingZhuang, Junling
- [24] Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)BLOOD, 2017, 130Ishida, TadaoOzaki, ShujiKimura, HideoKubo, KoumeiSunami, KazutakaTakezako, NaokiFujita, HiroyukiHayashi, ToshiakiKiguchi, ToruKobayashi, TakeshiYamamoto, SatoshiTakamatsu, HiroyukiKosugi, HiroshiOhta, KensukeSakai, RikaHanda, HiroshiHisatomi, TakashiAbe, YuSasaki, KoOmoto, EijiroMurakami, HirokazuShimizu, Kazuyuki
- [25] An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Laubach, JacobNooka, Ajay K.Cole, CraigO'Donnell, ElizabethVij, RaviUsmani, Saad ZafarOrloff, Gregory JoshuaRichter, Joshua RyanRedd, RobertDiPietro, HeidiCummings, KristenHansen, JoshuaHenrick, Patrick M.Bassett, PaulSchachter, HaleyRichardson, Paul G.Lonial, Sagar
- [26] An Ongoing Phase 2, Multi-Center, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease PatientsHEPATOLOGY, 2016, 64 : 281A - 282ASchilsky, Michael L.Askari, Frederick K.Ferenci, PeterCzlonkowska, AnnaNicholl, David J.Bronstein, JeffreyBega, DannyWeiss, Karl Heinz
- [27] A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma PatientsBLOOD, 2010, 116 (21) : 808 - 808Palumbo, AntonioFalco, PatriziaBenevolo, GiuliaRossi, DavideCarella, Angelo MicheleGuglielmelli, TommasinaRocci, AlbertoDe Paoli, LorenzoGrasso, MariellaSiez, Maria Letizia MoscaPiro, EugenioCaltagirone, SimonaGay, FrancescaCavallo, FedericaGaidano, GianlucaBoccadoro, Mario
- [28] Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study GroupBLOOD, 2016, 128 (22)Terpos, EvangelosKatodritou, EiriniSymeonidis, ArgirisZagouri, FloraGerofotis, AntonisChristopoulou, GeorgiaGavriatopoulou, MariaChristoulas, DimitriosKourakli, AlexandraKonstantinidou, PavlinaKastritis, EfstathiosDimopoulos, Meletios A.
- [29] Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialLANCET HAEMATOLOGY, 2023, 10 (10): : E825 - E837Voorhees, Peter M.Sborov, Douglas W.Laubach, JacobKaufman, Jonathan L.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D.Nathwani, NityaShah, NinaBumma, NareshEfebera, Yvonne A.Holstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Dinner, ShiraPei, HuilingCortoos, AnnelorePatel, SharmilaLin, Thomas S.Usmani, Saad Z.Richardson, Paul G.
- [30] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.BLOOD, 2015, 126 (23)Ishida, TadaoKimura, HideoKubo, KoumeiSunami, KazutakaOzaki, ShujiTakezako, NaokiHanda, HiroshiKosugi, HiroshiMurakami, HirokazuShimizu, Kazuyuki